Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoSABR: SBRT + Darleukin in Limited Metastatic NSCLC
NCT02735850Phase 2Withdrawn
- Sponsor
- Maastro Clinic
- Start
- Dec 2015
- Primary completion
- Feb 2021
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of darleukin in non-small cell lung cancer (NSCLC), sponsored by Maastro Clinic. Planned start Dec 2015; status: withdrawn.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02735850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735850.